Production and radiochemical purity of 177Lu-PSMA-617 for clinical trial

被引：0
|
作者：
Asad, Ali [1 ]
Scharli, Rainer [2 ]
Morandeau, Laurence [1 ]
Price, Roger [3 ]
机构：
[1] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[2] Univ Western Australia, Nedlands, WA, Australia
[3] Sir Charles Gairdner Hosp, Med Technol & Phys, Nedlands, WA, Australia
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
P-358
引用
收藏
页码：S527 / S527
页数：1
相关论文
共 50 条
  • [41] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [42] 177Lu-PSMA-617 therapy in Chemotherapy Naive patients: A single center experience
    Kulkarni, Raksha
    Abdelrahman, Ahmed
    Novello, Matteo
    Cengiz, Turgut Bora
    Akinlusi, Rahman
    Bander, Ilda
    Patel, Vaibhav
    Wise, David
    Ghesani, Munir
    Ghesani, Nasrin
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [43] 177Lu-PSMA-617 Therapy in a Patient on Haemodialysis with End Stage Renal Failure
    MacFarlane, L.
    Eifer, M.
    Saghebi, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S248 - S248
  • [44] Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617
    Kristiansson, Amanda
    Timmermand, Oskar Vilhelmsson
    Altai, Mohamed
    Strand, Joanna
    Strand, Sven-Erik
    Akerstrom, Bo
    Orbom, Anders
    PHARMACEUTICS, 2022, 14 (04)
  • [45] The additive value of fractionated 177Lu-PSMA-617 administration in treating prostate cancer
    Zheng, Xiaobei
    Cui, Bin
    Hou, Wenli
    Zhao, Zhongqi
    He, Shuhua
    Li, Xiao
    Xue, Shuai
    Luo, Xiu
    Ma, Li
    Zhang, Lan
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2025, 334 (01) : 99 - 104
  • [46] Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability
    Suman, Sonam
    Parghane, Rahul V.
    Joshi, Amit
    Prabhash, Kumar
    Talole, Sanjay
    Basu, Sandip
    PROSTATE, 2021, 81 (15): : 1225 - 1234
  • [47] First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
    van Kalmthout, Ludwike
    Braat, Arthur
    Lam, Marnix
    van Leeuwaarde, Rachel
    Krijger, Gerard
    Ververs, Tessa
    Mehra, Niven
    Bins, Adriaan
    Hunting, Jarmo
    de Keizer, Bart
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 446 - 451
  • [48] Prognostic value of baseline imaging parameters prior to therapy with 177Lu-PSMA-617
    Ferdinandus, Justin
    Thang, Sue Ping
    Violet, John
    Hicks, Rodney
    Sandhu, Shahneen
    Hofman, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [49] Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Kiess, Ana
    Lukens, J. Nicholas
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2025, 15 (01) : 14 - 18
  • [50] Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC A Proof-of-Principle Application
    Bal, Chandrasekhar
    Yadav, Madhav Prasad
    Ballal, Sanjana
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (08) : E386 - E387
12345